News

Eli Lilly files lawsuits over other companies selling Zepbound and Mounjaro
INDIANAPOLIS — Eli Lilly filed lawsuits against compounding pharmacies and an Indianapolis weight loss company over the use of Zepbound and Mounjaro. On April 1, 2025, Lilly filed lawsuits against two ...
Mounjaro went head-to-head against Wegovy with one clear winner as the new 'weight loss jab' to be rolled out across UK
A trial pitting weight loss jab Mounjaro against competitor Wegovy ended with one clear winner, and Mounjaro is getting ...
Adam Parker of Trivariate Research Recommends Eli Lilly’s Dividend as a Defensive Play
Eli Lilly and Company (NYSE:LLY) is one of Best Dividend Stocks to Buy for Dependable Dividend Growth. According to Adam ...
Doctor issued warning over potentially fatal Mounjaro 'golden dose' as weight-loss jab to be rolled out across Britain
Mounjaro will soon be available on the NHS across the UK but it's important patients avoid the dangerous 'golden dose' trend ...
Can Mounjaro, Zepbound Help Lilly Maintain Dominance in Obesity Space?
Eli Lilly’s LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Both ...
Eli Lilly Co. to buy gene-editing startup Verve to develop cardiac drugs
Eli Lilly will buy Boston-based Verve Therapeutics, Inc. in a billion dollar deal with plans to advance Verve's new line of ...
Eli Lilly's weight loss drug Mounjaro sales bulk up 60% on dosage upgrade
Eli Lilly’s diabetes and obesity management drug Mounjaro saw a sharp rise in sales for the third consecutive month, driven ...
Lilly Moves Past 50-Day Average: Should You Buy the Stock Now?
LLY breaks above its 50-day average as Mounjaro and Zepbound drive revenues. Is this a new entry point for investors?
EconoTimes3d
Eli Lilly Nears $1.3B Acquisition of Gene Editing Firm Verve Therapeutics
Eli Lilly and Company (NYSE: LLY) is reportedly in advanced talks to acquire gene editing biotech Verve Therapeutics Inc.